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ORIGINAL ARTICLE

Peripheral Blood Monocyte Gene Expression Proﬁle
Clinically Stratiﬁes Patients With Recent-Onset
Type 1 Diabetes
Katharine M. Irvine,1 Patricia Gallego,2,3 Xiaoyu An,1 Shannon E. Best,1 Gethin Thomas,1
Christine Wells,4 Mark Harris,2 Andrew Cotterill,2 and Ranjeny Thomas1

T

he most promising stage for therapeutic intervention in type 1 diabetes is presently at diagnosis, with the goal of prolonging remission and
preserving residual b-cell mass. However, the
rate of type 1 diabetes progression is heterogeneous and
unpredictable. The quality of glycemic control in early disease has far-reaching implications for disease progression
and the development of diabetes complications (1). Younger age, presentation with diabetic ketoacidosis, a history of
viral infection, or low adiponectin (a marker of insulin resistance) have been associated with a low frequency of
remission (2–4), but no biomarkers offering insight into the
immunological basis of disease progression have so far
been identiﬁed. Such biomarkers would also assist trial
design. For example, immunotherapies in recent trials
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temporarily delayed disease progression, but treated patients eventually deteriorated on a similar trajectory to
control subjects (5).
The versatile cells of the innate immune system, including peripheral blood (PB) monocytes and their differentiated tissue progeny, macrophages, and dendritic cells
(DCs), are powerful sensors of stress and danger and
mediators of tissue repair. In their role as antigen presenting cells, they orchestrate adaptive immune responses
to both endogenous and pathogen-mediated host damage.
Paradoxically, innate immune activation may play both
pathological and protective roles in type 1 diabetes, depending on disease stage and context (6). At a molecular
level, there is substantial evidence for dysregulated innate
immunity in type 1 diabetes (7–10), both before and after
disease onset. Activated macrophages and DCs are observed in rodent pancreatic islets before lymphocyte recruitment and are thought to be the primary source of the
proinﬂammatory cytokines tumor necrosis factor (TNF),
interleukin (IL)-6, and IL-1b that are implicated in type 1
diabetes pathogenesis (11). Macrophages are also found in
islets from recent-onset type 1 diabetic patients (12). In
contrast with their proinﬂammatory roles, macrophages
also have immunoregulatory and tissue repair roles, which
may be critical in restraining b-cell destruction. Diabetes
was exacerbated in mice that lack colony stimulating
factor (CSF)-1–dependent pancreatic macrophages, whereas
macrophages promoted b-cell survival and function in a
CSF-1–dependent manner (13,14).
We hypothesized that PB monocyte phenotype and
function constitute sensitive indicators of the prodiabetes
microenvironment, making them ideal biomarkers of innate
immune status in type 1 diabetes. Previous PB screening
approaches identiﬁed proinﬂammatory signatures, although
these studies were in mixed cell populations and were
frequently complicated by the proinﬂammatory effects
of hyperglycemia (8,9). We characterized monocyte gene
expression in insulin-treated type 1 diabetic patients 3
months after disease onset and analyzed clinical features
from diagnosis to 1 year. We report a PB monocyte expression proﬁle, which clinically stratiﬁes glycemic control
within the ﬁrst year after type 1 diabetes diagnosis.
RESEARCH DESIGN AND METHODS
Study population. Sixteen children with recently diagnosed type 1 diabetes
(;3 months postdiagnosis; Table 1) were recruited at the Mater Children’s
Hospital during 2009 and 2010. Informed consent was obtained from all participants, and the studies were approved by the Mater Health Services and
Princess Alexandra Hospital Human Research Ethics Committees. Consenting
adult blood donors were used as healthy control subjects for the microarray
study (33% female, mean [SD] age 32 years (8.2 years), BMI 24.5 [1.2]), whereas
age-matched children without a family history of autoimmune disease recruited
from operation list patients awaiting nonurgent surgery served as control subjects
DIABETES, VOL. 61, MAY 2012
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Novel biomarkers of disease progression after type 1 diabetes
onset are needed. We proﬁled peripheral blood (PB) monocyte
gene expression in six healthy subjects and 16 children with type 1
diabetes diagnosed ;3 months previously and analyzed clinical
features from diagnosis to 1 year. Monocyte expression proﬁles
clustered into two distinct subgroups, representing mild and severe deviation from healthy control subjects, along the same
continuum. Patients with strongly divergent monocyte gene expression had signiﬁcantly higher insulin dose–adjusted HbA1c
levels during the ﬁrst year, compared with patients with mild
deviation. The diabetes-associated expression signature identiﬁed multiple perturbations in pathways controlling cellular metabolism and survival, including endoplasmic reticulum and
oxidative stress (e.g., induction of HIF1A, DDIT3, DDIT4, and
GRP78). Quantitative PCR (qPCR) of a 9-gene panel correlated
with glycemic control in 12 additional recent-onset patients. The
qPCR signature was also detected in PB from healthy ﬁrst-degree
relatives. A PB gene expression signature correlates with glycemic
control in the ﬁrst year after diabetes diagnosis and is present in atrisk subjects. These ﬁndings implicate monocyte phenotype as
a candidate biomarker for disease progression pre- and postonset and systemic stresses as contributors to innate immune
function in type 1 diabetes. Diabetes 61:1281–1290, 2012

MONOCYTE PROFILE IN RECENT-ONSET TYPE 1 DIABETES

TABLE 1
Characteristics of group A and group B type 1 diabetic patients at diagnosis

n
Female (%)
Age at diagnosis (years 6 SD)
BMI at diagnosis (6 SD)
Number of patients with $1 islet autoantibody (%)
Mean glucose at diagnosis (mmol/L 6 SD)
Mean %HbA1c at diagnosis (6 SD)
Mean C-peptide at diagnosis (nmol/L 6 SD)
Mean 25-OH-vitamin D at diagnosis (nmol/L 6 SD)
Number of patients presenting with DKA (%)
Mean HCO32 at diagnosis (mmmol/L 6 SD)
Number of patients with celiac disease
Number of patients with high-risk HLADQ genotype**

Group A

Group B

P

9
5 (56)
11.5 6 2.9
20.2 6 6.1
7 (78)
24.5 6 6.0
13.2 6 0.9
0.19 6 0.1
93.2 6 37.1
6 (78)
15.2 6 8.3
1
5/7*

7
5 (71)
11.6 6 2.8
20.3 6 3.1
7 (100)
26.4 6 12.1
13.4 6 2.3
0.13 6 0.03
95.0 6 25.6
4 (57)
18.3 6 6.3
1
3/5*

0.63
0.94
0.95
0.48
0.69
0.86
0.17
0.91
0.64
0.43
1
1

for ﬂow cytometry and peripheral blood mononuclear cell (PBMC) quantitative
PCR (qPCR) (mean age [SD] 10 years [4.2 years]). Blood samples were obtained
from ﬁrst-degree relatives (FDR) of type 1 diabetic patients with informed
consent (mean age [SD] 9 years (3.9 years). Insulin dose–adjusted glycosylated
hemoglobin (HbA1c) (IDAA1c) was calculated as %HbA1c + 4 3 (insulin dose
[units/kg/day]) (15). Diabetic ketoacidosis (DKA) at presentation was deﬁned
as ,22 mmol/L plasma bicarbonate.
Monocyte puriﬁcation, expression proﬁling, and qPCR. CD14+ monocytes were puriﬁed from Ficoll-puriﬁed PBMC by positive selection (MACS,
Miltenyi). Total RNA was puriﬁed from CD14+ monocytes using RNeasy Mini
columns, with on-column DNase digestion (Qiagen). RNA from the donors
selected for microarray (500 ng; Agilent Bioanalyzer RNA Integrity Score .8)
was ampliﬁed using the Totalprep RNA ampliﬁcation kit (Ambion). Ampliﬁed
RNA was hybridized to Illumina HT-12 v3.0 whole genome beadarrays,
according to the manufacturer’s instructions. Beadarrays were scanned on an
Illumina iScan, and raw data were exported from BeadStudio (Illumina) for
further analysis. Gene expression data have been deposited in the gene expression omnibus (GEO) database (GSE33440, Reviewer Access: http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?token=dvezxukmesmsohe&acc=GSE33440).
Data were variance stabilized and quantile normalized using the Lumi package
in R (Bioconductor, http://www.bioconductor.org/packages/2.0/bioc/html/lumi.
html), followed by clustering and differential expression analysis in GenespringGX
(Agilent). Probes that did not achieve an Illumina Detection P value = 0 in $1
sample were omitted from the analysis. Genes whose expression was signiﬁcantly correlated with plasma glucose or %HbA1c were identiﬁed by quantitative
trait analysis in BRB-ArrayTools, developed by Dr. Richard Simon and the
BRB-ArrayTools Development Team (Pearson correlation, P , 0.001). Probes
identiﬁed as signiﬁcantly up- or downregulated in T1D-B monocytes were
analyzed for ontology enrichment using Database for Annotation, Visualization
and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov/). Functional
Annotation Charts generated using Level 4 Bioprocess Gene Ontology terms,
with the Illumina HT-12 genome as background, were manually curated to remove
redundant annotations. OligodT-primed cDNA was synthesized from 1 mg RNA
(Quantace). qPCR was performed using Sensimix SYBR mastermix (Quantace)
on an Agilent HT-7900. Gene expression relative to hypoxanthine-guanine
phosphoribosyltransferase was calculated using the DCt method. Mediannormalized qPCR data were clustered in GenespringGX. qPCR primer sequences
used in this study appear in Supplementary Table 1.
Flow cytometry. Whole blood (50 mL) was stained with anti–CD14-FITC,
anti–CD16-PaciﬁcBlue, anti–CX3CR1-Alexa647, or corresponding isotype
controls (Biolegend or Becton Dickinson) and Aqua live/dead discriminator
(Invitrogen) for 20 min. Erythrocytes were lysed with the addition of 450 mL
FACS Lysing Solution (Becton Dickinson) for 5 min, followed by sample ﬁxation with 100 mL of 1% formalin immediately before analysis on a Gallios ﬂow
cytometer (Beckman Coulter). Live, CD14+ cells were analyzed for CD14,
CD16, and CX3CR1 expression, with gates set according to negative controls,
which contained the isotype control for each antibody, as well as the rest of
the antibodies in the staining panel. Kaluza (Beckman Coulter) was used for
ﬂow cytometry compensation and analysis.
Statistical analysis. Except for microarray analysis, all statistical tests were
calculated in GraphPad Prism. Comparisons between groups were made with
unpaired t test or ANOVA; F test was used to check whether variances were
1282
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equal, and appropriate tests were used: unpaired t test if variances were equal,
with Welch’s correction if variances were unequal. Categorical variables were
compared using the Fisher exact probability test.

RESULTS

Stratiﬁcation of type 1 diabetic patients by monocyte
expression proﬁle at diagnosis. Puriﬁed PB CD14+
monocytes from a total of 16 recent-onset type 1 diabetic
patients and six healthy control subjects were expression
proﬁled using whole genome microarrays (Illumina
HT-12), in two separate, independent experiments. Because
of the volume of blood required to study puriﬁed monocytes,
the healthy control subjects comprised young adults. Blood
samples for microarray analysis were taken from insulintreated patients ;3 months after type 1 diabetes diagnosis,
to avoid the acute metabolic disturbance associated with
disease onset. A strikingly similar pattern was observed in
both experiments, whereby a subset of monocyte expression proﬁles clustered apart from the remaining patients
and healthy control subjects (group B, Fig. 1A and B). Because of this stark segregation, group B proﬁles were analyzed separately to identify differentially expressed genes.
In group B monocytes compared with healthy control
subjects in both microarrays (Fig. 1C and Supplementary
Table 2), 1,107 probes (1,015 genes) were at least 1.5-fold
differentially expressed (Benjamini Hochberg-corrected
P value ,0.05). Between the entire diabetes cohort and
healthy control subjects in both microarrays (Fig. 1D), 320
probes were differentially expressed. Only 38 probes were
reproducibly differentially expressed between group A
patients and healthy control subjects. Hierarchical clustering
of group B–regulated probes revealed that the two putative
type 1 diabetes subgroups represent a spectrum of deviation from healthy control subjects, along the same continuum (Fig. 2A and B).
Extreme divergence from healthy monocyte gene
expression correlates with early type 1 diabetes
progression. At diagnosis, group A and group B patients
were clinically indistinguishable in terms of HLA genotype,
family history, clinical presentation at diagnosis (including
symptom duration, ketoacidosis, blood glucose, 25-hydroxyvitamin D, diabetes-associated autoantibodies, or the presence of celiac or thyroid disease; Table 1 and data not
shown). Group B patients had higher levels of HbA1c 3 and 6
diabetes.diabetesjournals.org
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Biometrics and clinical parameters recorded at diagnosis of type 1 diabetes. P values calculated using two-tailed unpaired t test (discrete
variables) or Fisher exact probability test (categorical variables). HCO32, bicarbonate; DKA, diabetic ketoacidosis. *No genotyping data for 1
of 9 group A and 2 of 7 group B patients. **DQB1*0201, DQB1*0302 and/or DQA1*0501, DQA1*301.
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FIG. 1. Unsupervised clustering of monocyte gene expression proﬁles
identiﬁes a subgroup of recent-onset type 1 diabetic patients. Puriﬁed
PB monocytes from patients (D) or healthy control subjects (HC) (H)
were expression-proﬁled by Illumina whole genome microarray, in two
independent experiments (A, B). For each microarray, all genes detected
in ‡1 sample were clustered using the Euclidean Distance correlation.
Monocyte expression proﬁles from all patients, or the subset of patients
designated “B”, were used to identify genes that were signiﬁcantly
differentially expressed (‡1.5-fold differential expression, Benjamini
Hochberg corrected P < 0.05) between patients and control subjects
(C, D).

months after diagnosis (Fig. 3A) and required signiﬁcantly
higher insulin doses to maintain glycemic control in the ﬁrst
12 months after diagnosis (Fig. 3B, P = 0.0004, 2-way ANOVA).
Approximately 30% of children diagnosed with type 1 diabetes
experience a partial remission phase (honeymoon), during
which their HbA1c levels and insulin requirements (used as
a proxy for endogenous insulin production from residual
b-cells) (15) are relatively low. An insulin dose–adjusted
HbA1c metric (IDAA1c) #9 correlated with the deﬁnition of
C-peptide responders in the Diabetes Control and Complications Trial (16) and was proposed as a deﬁnition for partial
remission. Group A and group B IDAA1c diverged around
9 at 3–6 months postdiagnosis, and group B patients
exhibited signiﬁcantly higher IDAA1c during the ﬁrst year
of disease (Fig. 3C, P , 0.0001, 2-way ANOVA).
To examine whether the monocyte gene expression
proﬁles observed were directly related to hyperglycemia,
we identiﬁed probes whose expression was signiﬁcantly
correlated (Pearson P , 0.001) with plasma glucose concentration (n = 25), or %HbA1c (n = 70), at the time blood
was sampled for proﬁling. No glucose-correlated probes
diabetes.diabetesjournals.org

FIG. 2. Extremely divergent monocyte expression proﬁle in a subgroup of
recent-onset type 1 diabetic patients. Genes that were differentially
expressed between group B monocytes and healthy control subjects (HC)
(n = 1,107) in two independent microarrays were clustered using the Euclidean Distance correlation, as were the experimental samples (A, B).

and 9 of 70 HbA1c-correlated probes were differentially
expressed between group B and healthy control subject
monocytes (Supplementary Fig. 1). These analyses suggest
the innate immune status of group B monocytes is not solely
driven by hyperglycemia.
The group B monocyte proﬁle is a signature of
disturbed metabolic homeostasis. The correlation between monocyte gene expression close to type 1 diabetes
onset and early clinical trajectory may imply a role for
monocyte function in disease progression. Alternatively,
or additionally, because PB monocytes are professional
DIABETES, VOL. 61, MAY 2012
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stress-sensing cells that circulate throughout the body,
they may provide a window on systemic stresses, i.e.,
reﬂecting islet damage. We analyzed the set of 1,107
probes that were $1.53 up- or downregulated in group B
patients compared with healthy control subjects in both
arrays for signiﬁcantly enriched gene ontology terms.
Terms were manually curated to remove redundant categories comprising overlapping gene sets. Overexpressed
genes were enriched for cellular stress and activation
pathway genes, especially oxidative and endoplasmic reticulum (ER) stress (Fig. 4). We did not observe upregulation of classical inﬂammatory mediators, with the exception
of tumor necrosis factor (TNF), interleukin (IL)-10, and
PTGES2 (which encodes the enzyme catalyzing prostaglandin E2 production), and the prostaglandin E2 receptor,
1284
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FIG. 3. Diabetes progression in recent-onset type 1 diabetic patient
subgroups. Plasma levels of %HbA1c (A) and total daily insulin dose
(units/kg) (B) were recorded at 3 monthly intervals following diabetes
diagnosis, from which IDAA1c (C) was calculated. Mean %HbA1c, daily
insulin dose, and IDAA1c (6 SD) are shown for patients subgrouped
according to monocyte expression proﬁle (group A, ●; group B, ■).
Group sizes: HbA1c data: n = 8, 7, 7, and 7 for group A and n = 7, 7, 6, and
7 for group B at 3, 6, 9, and 12 months. TDD data: n = 8, 7, 6, and 4 for
group A and n = 6, 6, 5, and 4 for group B at 3, 6, 9, and 12 months.
Missing data arose when patients missed a clinic visit or commenced
a basal/bolus or insulin pump regimen.

PTGER (Supplementary Table 2 and Fig. 5), whereas multiple genes involved in regulation of immune responses
were downregulated in group B monocytes (Fig. 4). These
included sensors such as TLR4, TLR5, IFI16, NLRX1, and
NLRC4/IPAF and effectors such as CASP1 (Supplementary
Table 2). Ten genes in key pathways differentially expressed by group B monocytes were selected for qPCR
validation. Their expression was quantiﬁed in eight patients
proﬁled previously by microarray and 12 additional recentonset type 1 diabetic patients. Hierarchical clustering of 9
robustly detected genes segregated group B patients from
group A and healthy control subjects, whereas unclassiﬁed
patients’ monocytes (D) revealed a spectrum of gene expression, similar to the microarray analysis (Fig. 5A). IDAA1c
tended to increase with increasing distance from the healthy
control subjects expression proﬁle (Fig. 5B; 3 or 6 month
linear regression: slope = 20.225/20.176, P = 0.017/0.091).
Two genes selected for validation, DDIT4 and adrenomedullin (ADM), were not incorporated in the cluster analysis
since they were only detected in monocytes from a subset of
type 1 diabetic patients, including group B (Fig. 5C and D).
The group B monocyte expression proﬁle strongly suggested stress-induced metabolic disturbance, with upregulation of ER and oxidative stress responsive genes, and
downregulation of genes involved in cellular energy and
metabolite production, especially mitochondrial oxidative
phosphorylation (e.g., PDHB, MDH1, IDH1, SDHC, ACLY)
(Fig. 5 and Supplementary Table 1). Mitochondrion was
the most signiﬁcantly enriched cellular component ontology among group B downregulated genes (P = 2.6e-05). It
is well established that activation of myeloid and other
immune cells is accompanied by a switch in glucose metabolism and cellular energy production, from oxidative
phosphorylation to anaerobic fermentation through glycolysis (17). PFKFB3, which encodes the rate-limiting enzyme
in the glycolytic pathway, was upregulated in group B
monocytes (Fig. 5), but glycolytic pathway genes were not
generally induced. PDHB and PFKFB3 expression was
strongly inversely correlated in the microarray (r = 20.86,
P , 0.0001), which may imply a reduction in oxidative
phosphorylation and increased glycolysis (17). In addition
to perturbations in core metabolic pathways, there was
also evidence of cellular activation through stress, including the unfolded protein response that is a consequence of ER stress (e.g., IRE1, GRP78, DDIT3, XBP1)
(Fig. 5 and Supplementary Table 2). HIF1A, a key mediator
of oxidative stress, was upregulated in group B monocytes,
as were multiple HIF1A target genes, including DDIT4,
PFKFB3, and ADM (17,18) (Fig. 5 and Supplementary
Table 2). Thus, the striking group B monocyte expression
proﬁle is a mixed signature consistent with the existence of
multiple pathological processes and/or adaptive responses
to stress and inﬂammation.
Monocyte subset balance is altered in PB of type 1
diabetic patients and a subset of FDR. The mRNA
encoding CX3CR1, a marker of CD16+ monocytes (19),
was underexpressed in type 1 diabetic patients compared
with healthy control subjects (Fig. 5), suggesting this dysregulation could derive from a perturbation in PB monocyte
subset balance. PB monocytes from children with recentonset or established type 1 diabetic and healthy children
were phenotyped in whole blood according to surface expression of CD14 and CD16 (see Supplementary Fig. 2 for
representative ﬂow cytometric proﬁles). We observed a reduction in the total proportion of CD16+ monocytes in PB
of type 1 diabetic patients (not shown), which was as a

K.M. IRVINE AND ASSOCIATES

result of a selective reduction in the proportion of CD14Hi/
CD16+ monocytes (Fig. 6A). The proportions of CD14Low/
CD16+ and CD14Hi/CD162 populations were unaltered
(Fig. 6B and C), whereas the proportion of CD14Low/
CD162 cells was signiﬁcantly increased in recent-onset
type 1 diabetic patients (Fig. 6D). We observed a signiﬁcant reduction of CD14Hi/CD16+ monocytes and an increase in CD14Low/CD162 monocytes in FDR of children
with type 1 diabetes, relative to healthy children (Fig.
6E), suggesting that this ﬁnding is not associated with
hyperglycemia. This phenotype may be monocyte-intrinsic,
or may arise because of external sources of stress, which
could affect b-cell reserve and PB monocyte subsets in both
recent-onset patients and in FDR. The proportion of CD16+
monocytes in PB positively correlated with monocyte surface CX3CR1 expression by all CD14+ monocytes (Fig. 6F,
Pearson’s r = 0.4648, P , 0.0001), whereas CX3CR1 surface
expression by individual monocyte populations was not altered (data not shown). Thus, the distinctive monocyte
signature in recent-onset diabetes, which includes CX3CR1
repression, may partially derive from a relative deﬁciency in
CD14Hi/CD16+ monocytes and enrichment in CD14Low/
CD162 monocytes.
diabetes.diabetesjournals.org

Subtle changes in cellular composition could underpin
differential gene expression in a mixed cell population. We
thus investigated whether group B–regulated genes typically exhibited monocyte subset-speciﬁc expression patterns. In a meta-analysis of all 16 monocyte microarrays,
98 genes were signiﬁcantly correlated with CX3CR1 expression (Pearson, P , 0.001). Of the 1,109 genes that
were signiﬁcantly differentially expressed in group B monocytes ($1.53, P , 0.05), 64 were also correlated with
CX3CR1 expression (Supplementary Fig. 3). Given the
strong correlation between total monocyte CX3CR1 surface
expression and %CD16+ monocytes in PB, these represent
candidate subset-speciﬁc genes. We also analyzed two
public microarray datasets that compared CD14Hi/CD162,
CD14Hi/CD16+, and CD14Low/CD16+ monocyte gene
expression (20,21). There was negligible overlap between
the group B monocyte signature and the genes that were
differentially expressed between monocyte subsets (data
not shown).
ER and oxidative stress markers are upregulated in
FDR PBMC. To investigate whether elements of the group
B monocyte signature are evident in children at risk of
developing type 1 diabetes, we assayed gene expression in
DIABETES, VOL. 61, MAY 2012
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FIG. 4. Biological processes associated with group B differentially expressed genes. Gray bars indicate ontology enrichment within upregulated
genes; white bars indicate ontology enrichment within downregulated genes. Associated P values are indicated by the line. NF-kB, nuclear
factor-kB.
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PBMC from FDR, including 14 of 43 with at least one islet
autoantibody, compared with healthy children. Puriﬁed
monocytes were not studied since blood sample volumes
were limiting. Broadly expressed genes such as CX3CR1
and HIF1A were not differentially expressed between FDR
and healthy control subjects (data not shown). By contrast, increased expression of the inducible ER stress
(DDIT3, GRP78) and oxidative stress genes (DDIT4,
ADM), and the proinﬂammatory cytokine TNF, was evident in a subset of FDR (Fig. 7A–E). Expression levels of
several of these genes were highly correlated to each other
(P , 0.0001, Fig. 7F–H and data not shown), but their
expression did not differ between autoantibody positive
and negative FDR (not shown). Stress marker expression
did not correlate with monocyte subset distribution (Fig.
7I and J and data not shown), conﬁrming our conclusion
from the meta-analysis that the stress signature is coincident with, but distinct from, altered monocyte subset
distribution in type 1 diabetic patients and FDR.
DISCUSSION

There is considerable interest in developing therapies to
protect and regenerate residual b-cell function, to arrest
or slow the course of disease, and to mitigate the development of type 1 diabetes complications (5). This
should be achievable, since 80% juvenile diabetic patients
1286
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had signiﬁcant residual b-cell function during the ﬁrst year
after diagnosis (22). However, disappointing results in
several recent Phase III immunotherapy trials in recentonset type 1 diabetes have invited speculation that factors,
such as b-cell stress, contribute to continuing b-cell destruction after disease onset and may require treatments
other than immune intervention (23).
We report here that PB of children with type 1 diabetes
is characterized by a relative deﬁciency of CD14Hi/CD16+
monocytes, an enrichment in CD14Low/CD162 monocytes, and a striking, coordinated monocyte gene expression reﬂecting altered metabolism associated with stress.
Recent-onset patients could be reproducibly stratiﬁed on
the basis of their monocyte gene expression proﬁle. Severe
deviation from a healthy monocyte expression proﬁle,
which we observed in ;50% of patients, independently
identiﬁed a clinical subset with reduced glycemic control, as evidenced by higher %HbA1c and higher insulin
requirement. We hypothesize that the two ends of the
spectrum at type 1 diabetes onset represent different disease trajectories, whose differences in glycemic control
may affect future development of diabetes complications
(1). Identiﬁcation of individuals on a severe trajectory may
provide opportunities for better clinical management or
targeted therapies for these patients. The reason for the
early clinical divergence in these patients is not clear, but
diabetes.diabetesjournals.org
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FIG. 5. Quantitative PCR (qPCR) validation of monocyte gene expression proﬁles in recent-onset type 1 diabetes. The expression of 9 group B–
regulated genes was quantiﬁed by real time qPCR in CD14+ monocytes, relative to hypoxanthine-guanine phosphoribosyltransferase expression.
Relative expression values for each gene were normalized to the gene’s median expression across all samples. Genes and samples were clustered
by Spearman correlation (A). Group A and group B patients were classiﬁed previously by microarray. D denotes recent-onset patients who were
followed from diagnosis with monocyte sampling at 3 months, but not proﬁled by microarray. IDAA1c corresponding to each patient proﬁle in A
recorded 3 (circles) and 6 (squares) months postdiagnosis (B) is shown. Missing data arose when patients missed a clinic visit or commenced
a basal/bolus or insulin pump regimen. Relative expression of DDIT4 (C) and ADM (D) in the patient cohort depicted in A and B is shown.
Transcript detection rates appear in parentheses. HC, healthy control subjects.
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could be explained by two testable hypotheses: 1) pathological processes are intrinsically more aggressive, or
regulation less effective, in group B patients than group A
patients or 2) group A patients possess the greater b-cell
reserve at diagnosis, and insulin treatment enables at least
transient restoration of function in these cells.
Type 1 diabetes progression is most commonly assessed
using metabolic parameters, including %HbA1c, insulin requirement, and C-peptide levels. C-peptide is the most
common surrogate marker for declining b-cell function,
and thus rate of disease progression. Higher %HbA1c and
insulin requirements were associated with rapid disease
progression in several prospective studies, along with risk
factors such as younger age, presentation with ketoacidosis,
and GAD autoantibody status (4,24,25). Percent HbA1c
levels also predict the development of microvascular complications of type 1 diabetes (26). Type 1 diabetes progression and remission have rarely been studied from an
immunological perspective, although increased numbers
of regulatory T cells were associated with remission in
one small cohort study (27). It remains to be determined
whether monocyte phenotype represents an independent
biomarker for disease progression or whether monocytes
are simply stress-prone cells that reﬂect pancreatic dysfunction. Notably, the mRNA encoding ADM, a vasoactive
hormone involved in protection against oxidative stress
associated with diabetes complications and dysglycemia
(25,28), was upregulated in group B patients and FDR.
diabetes.diabetesjournals.org

Reactive oxygen species (ROS), the causative agents of
oxidative stress, are produced in response to environmental stimuli and as by-products of cellular metabolism.
The distinct oxidative and ER stress signature we observed in group B patients suggests these patients’ monocytes are intrinsically vulnerable to stress, or that they
exist in a stressful environment. Stress pathway activation
has implications for monocyte differentiation and function.
In addition to the elevated expression of oxidative stress
responsive genes, such as HIF1A and HIF1A targets, multiple genes involved in cellular antioxidant pathways were
downregulated in group B monocytes (e.g., CAT, G6PD,
OXR1, PRDX1, and PRDX3), suggesting protective mechanisms may be impaired. Oxidative stress is strongly implicated in type 1 diabetes progression, particularly in the
development of complications, in both humans and animal
models (29,30). Oxidative stress is directly associated with
b-cell toxicity and decreased insulin secretion, since
b-cells have intrinsically low antioxidant defenses (29), but
systemic oxidative stress may also play a role in promoting
hyperglycemia and diabetes progression. Monocytes and
neutrophils from type 1 diabetic subjects generated more
ROS (31), and macrophage-derived ROS were found to be
critical for the induction of autoreactive T cells and diabetes development in NOD mice (32).
Oxidative and ER stress are closely linked. Correct ERdependent protein folding is essential for the localization
and function of secreted and membrane-bound proteins.
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FIG. 6. Peripheral blood monocyte subset distribution in type 1 diabetic patients and their at-risk relatives. The percentage of monocytes in each of
the 4 monocyte subsets was determined by ﬂow cytometry analysis of surface CD14 and CD16 expression in whole PB. A–D: PB monocyte subset
distribution was determined for healthy control subjects (HC) (circles), long-standing type 1 diabetic patients (D, squares, >12 months after
diagnosis), recent-onset type 1 diabetic patients within 3 months of diagnosis (D[Dx], triangles). PB monocyte subset distribution in healthy
control subjects (ﬁlled shapes) and FDR (unﬁlled shapes) (E) is shown. Correlation between %CD14+/CD16+ monocytes and monocyte CX3CR1
surface expression (F) is shown. ***P < 0.0001; **P < 0.01; *P < 0.05.
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FIG. 7. Elements of the type 1 diabetes group B expression signature detected in healthy FDR PBMC. Expression of DDIT3 (A), GRP78 (B), DDIT4
(C), ADM (D), and TNF (E) in PBMCs from type 1 diabetic FDR or healthy children (HC) was quantitated by PCR. Correlation between DDIT3
and GRP78 expression levels (F) is shown. Correlation between DDIT4 and ADM expression levels (G) is shown. Correlation between TNF and
ADM expression levels (H) is shown. Correlation between DDIT3 expression and %CD14Hi/CD16+ (I) and %CD14Low/CD162 (J) monocytes in PB
is shown. P values for group comparisons (A–D) were generated by Student t test (with Welch’s correction where variances were signiﬁcantly
different, as determined by F test). Pearson’s correlation coefﬁcient (r) and associated P values are shown in E–G.
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inﬂammation and autoimmunity (49). Wound healing is
defective in humans and mice with diabetes, due in part to
an inability to efﬁciently clear apoptotic cells (50). Thus,
a relative deﬁciency in CD16+ monocytes may compromise
tissue repair and/or autoimmune regulation at sites of inﬂammation, including the pancreas, which would likely
promote disease progression and complications.
In conclusion, we demonstrate that monocyte gene expression distinguishes type 1 diabetic patients at disease
onset. This stratiﬁcation correlates with early disease trajectory, which we hypothesize has implications for the rate
of disease progression and the development of complications. The coordinated expression signature in rapidly
progressing type 1 diabetes suggests an underlying highlevel susceptibility or exposure to physiological stress.
Further studies will clarify the impact of the group B
monocytes phenotype on antigen-presenting cell function,
and thus T cell responses in autoimmune diabetes.
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